France Oncolytic Virus Market Insight
Published: 14 May 2026 | Report Format: Electronic (PDF)
France Oncolytic Virus market size is growing at a 15.8% CAGR, driven by rising cancer prevalence, increased immunotherapy research investments, expanding clinical trials for viral treatments, and demand for targeted cancer therapies.
France Oncolytic Virus Market Insights Forecasts to 2035
- The France Oncolytic Virus Market Size Was Estimated at USD 110.2 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 15.8% from 2025 to 2035
- The France Oncolytic Virus Market Size is Expected to Reach USD 478.01 Million by 2035
Notable Insights for France Oncolytic Virus Market
- The adenovirus segment leads the market because it holds the largest market share which will generate revenue of about USD 38 million for the year 2025.
- The solid tumors segment shows the highest growth rate in the market which will achieve a compound annual growth rate of approximately 16% between 2025 and 2035 because of increasing targeted oncology research and immunotherapy adoption.
- Solid tumors account for approximately 55% of oncolytic virus demand in France while 20% of demand supports melanoma immunotherapy research.
- Adenovirus-based therapies generate 35% of market revenue in France while HSV-based viral oncology treatments account for almost 20% of revenue because of active clinical development work.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the France Oncolytic Virus market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in France Oncolytic Virus Market
- Amgen
- Takara Bio
- CG Oncology
- Replimune Group
- Sorrento Therapeutics
- Oncolytics Biotech
- Pfizer
- Merck & Co.
- Transgene
- Viralytics
- Others
Recent Developments:
- In April 2026, Amgen expanded its oncolytic immunotherapy research initiatives targeting advanced melanoma and solid tumor treatment applications in Europe.
- In January 2026, Replimune Group strengthened its clinical development pipeline for next-generation oncolytic viral therapies combined with immune checkpoint inhibitors.
Market Segmentation:
France Oncolytic Virus Market, By Virus Type
- Adenovirus
- Herpes Simplex Virus (HSV)
- Vaccinia Virus
- Reovirus
- Others
France Oncolytic Virus Market, By Application
- Solid Tumors
- Melanoma
- Lung Cancer
- Breast Cancer
- Others
France Oncolytic Virus Market, By End-User
- Hospitals
- Cancer Research Institutes
- Specialty Oncology Clinics
- Others
Expert Views:
The France oncolytic virus market demonstrates rapid development because of the growing interest in cancer immunotherapy and precision oncology and targeted viral treatment technologies. Experts predict sustained market expansion which will result from increased clinical trial activities and biotechnology advancements and higher use of combination immunotherapy in cancer treatment.